

**Ivermectin / Abamectin Liquid Formulation**

Version 9.1      Revision Date: 30.09.2023      SDS Number: 1210015-00023      Date of last issue: 04.04.2023  
Date of first issue: 10.01.2017

---

**Section 1: Identification**

Product name : Ivermectin / Abamectin Liquid Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908  
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON)    0800 243 622 (0800 CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**Section 2: Hazard identification****GHS Classification**

Acute toxicity (Oral) : Category 4

Acute toxicity (Inhalation) : Category 4

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 2

Reproductive toxicity : Category 1

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - single exposure : Category 3

Specific target organ toxicity - repeated exposure : Category 2 (Central nervous system)

Hazardous to the aquatic environment - acute hazard : Category 1

## Ivermectin / Abamectin Liquid Formulation

Version 9.1      Revision Date: 30.09.2023      SDS Number: 1210015-00023      Date of last issue: 04.04.2023  
 Date of first issue: 10.01.2017

Hazardous to the aquatic environment - chronic hazard : Category 1

**GHS label elements**

Hazard pictograms :



Signal word : Danger

Hazard statements : H302 + H332 Harmful if swallowed or if inhaled.  
 H315 Causes skin irritation.  
 H319 Causes serious eye irritation.  
 H335 May cause respiratory irritation.  
 H360Df May damage the unborn child. Suspected of damaging fertility.  
 H371 May cause damage to organs (Central nervous system) if swallowed.  
 H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.  
 H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements :

**Prevention:**

P201 Obtain special instructions before use.  
 P260 Do not breathe mist or vapours.  
 P264 Wash skin thoroughly after handling.  
 P270 Do not eat, drink or smoke when using this product.  
 P271 Use only outdoors or in a well-ventilated area.  
 P273 Avoid release to the environment.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.  
 P302 + P352 IF ON SKIN: Wash with plenty of water.  
 P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.  
 P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
 P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
 P332 + P313 If skin irritation occurs: Get medical advice/ attention.  
 P337 + P313 If eye irritation persists: Get medical advice/ attention.  
 P391 Collect spillage.

**Storage:**

## Ivermectin / Abamectin Liquid Formulation

Version 9.1      Revision Date: 30.09.2023      SDS Number: 1210015-00023      Date of last issue: 04.04.2023  
 Date of first issue: 10.01.2017

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**Section 3: Composition/information on ingredients**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
N-Methyl-2-pyrrolidone	872-50-4	>= 20 -< 30
Ivermectin	70288-86-7	>= 1 -< 2.5
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	>= 1 -< 2.5
(dl)-a-Tocopheryl acetate	7695-91-2	< 0.1

**Section 4: First-aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
If not breathing, give artificial respiration.  
If breathing is difficult, give oxygen.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Harmful if swallowed or if inhaled.  
Causes skin irritation.  
Causes serious eye irritation.  
May cause respiratory irritation.  
May damage the unborn child. Suspected of damaging fertili-

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

ty.  
 May cause damage to organs if swallowed.  
 May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

---

**Section 5: Fire-fighting measures**

Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
 Nitrogen oxides (NO<sub>x</sub>)

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
 Use water spray to cool unopened containers.  
 Remove undamaged containers from fire area if it is safe to do so.  
 Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
 Use personal protective equipment.

Hazchem Code : 3Z

---

**Section 6: Accidental release measures**

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
 Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
 Prevent further leakage or spillage if safe to do so.  
 Prevent spreading over a wide area (e.g. by containment or oil barriers).  
 Retain and dispose of contaminated wash water.  
 Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
 For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
 Clean up remaining materials from spill with suitable absorbent.  
 Local or national regulations may apply to releases and dis-

## Ivermectin / Abamectin Liquid Formulation

Version 9.1	Revision Date: 30.09.2023	SDS Number: 1210015-00023	Date of last issue: 04.04.2023 Date of first issue: 10.01.2017
----------------	------------------------------	------------------------------	---

posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### Section 7: Handling and storage

- |                             |   |   |
|-----------------------------|---|---|
| Technical measures          | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.   |
| Local/Total ventilation     | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.   |
| Advice on safe handling     | : | Do not get on skin or clothing.<br>Do not breathe mist or vapours.<br>Do not swallow.<br>Do not get in eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures            | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.<br>When using do not eat, drink or smoke.<br>Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.  |
| Conditions for safe storage | : | Keep in properly labelled containers.<br>Store locked up.<br>Keep tightly closed.<br>Keep in a cool, well-ventilated place.<br>Store in accordance with the particular national regulations.  |
| Materials to avoid          | : | Do not store with the following product types:<br>Strong oxidizing agents   |

### Section 8: Exposure controls/personal protection

#### Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
------------	---------	------------	-----------------	-------

## Ivermectin / Abamectin Liquid Formulation

Version 9.1      Revision Date: 30.09.2023      SDS Number: 1210015-00023      Date of last issue: 04.04.2023  
 Date of first issue: 10.01.2017

		(Form of exposure)	ters / Permissible concentration	
N-Methyl-2-pyrrolidone	872-50-4	WES-TWA	25 ppm 103 mg/m <sup>3</sup>	NZ OEL
Further information: Skin absorption				
		WES-STEL	75 ppm 309 mg/m <sup>3</sup>	NZ OEL
Further information: Skin absorption				
Ivermectin	70288-86-7	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
Further information: Skin				
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	150 µg/100 cm <sup>2</sup>	Internal
(dl)-a-Tocopheryl acetate	7695-91-2	TWA	5000 µg/m <sup>3</sup> (OEB 1)	Internal

**Biological occupational exposure limits**

Components	CAS-No.	Control parameters	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type

Hand protection

Material : Chemical-resistant gloves

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

---

**Section 9: Physical and chemical properties**

Appearance	:	liquid
Colour	:	light yellow
Odour	:	characteristic
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	> 100 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	0.91 - 1.00 mg/l

## Ivermectin / Abamectin Liquid Formulation

Version 9.1      Revision Date: 30.09.2023      SDS Number: 1210015-00023      Date of last issue: 04.04.2023  
Date of first issue: 10.01.2017

---

Solubility(ies)  
Water solubility : insoluble

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

---

**Section 10: Stability and reactivity**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

**Section 11: Toxicological information**

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Harmful if swallowed or if inhaled.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 1,031 mg/kg  
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 1.84 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: Calculation method



## Ivermectin / Abamectin Liquid Formulation

Version 9.1      Revision Date: 30.09.2023      SDS Number: 1210015-00023      Date of last issue: 04.04.2023  
Date of first issue: 10.01.2017

---

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****N-Methyl-2-pyrrolidone:**

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

**Ivermectin:**

Acute oral toxicity : LD50 (Rat): 50 mg/kg  
LD50 (Mouse): 25 mg/kg  
LD50 (Monkey): > 24 mg/kg  
Target Organs: Central nervous system  
Symptoms: Vomiting, Dilatation of the pupil  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg  
LD50 (Rat): > 660 mg/kg

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Acute oral toxicity : LD50 (Rat): 24 mg/kg  
LD50 (Mouse): 10 mg/kg  
LDLo (Monkey): 24 mg/kg  
Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg  
LD50 (Rabbit): 2,000 mg/kg

**Ivermectin / Abamectin Liquid Formulation**

Version 9.1      Revision Date: 30.09.2023      SDS Number: 1210015-00023      Date of last issue: 04.04.2023  
Date of first issue: 10.01.2017

---

**(dl)-a-Tocopheryl acetate:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute dermal toxicity : LD50 (Rat): > 3,000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Result : Skin irritation

**Ivermectin:**

Species : Rabbit  
Result : No skin irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rabbit  
Result : No skin irritation

**(dl)-a-Tocopheryl acetate:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days

**Ivermectin:**

Species : Rabbit  
Result : Mild eye irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rabbit  
Result : Mild eye irritation

**(dl)-a-Tocopheryl acetate:**

Species : Rabbit

**Ivermectin / Abamectin Liquid Formulation**

Version 9.1      Revision Date: 30.09.2023      SDS Number: 1210015-00023      Date of last issue: 04.04.2023  
Date of first issue: 10.01.2017

---

Result : No eye irritation  
Method : OECD Test Guideline 405

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Test Type : Local lymph node assay (LLNA)  
Exposure routes : Skin contact  
Species : Mouse  
Method : OECD Test Guideline 429  
Result : negative  
Remarks : Based on data from similar materials

**Ivermectin:**

Exposure routes : Dermal  
Species : Humans  
Result : Does not cause skin sensitisation.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Result : Not a skin sensitizer.

**(dl)-a-Tocopheryl acetate:**

Test Type : Draize Test  
Exposure routes : Skin contact  
Species : Humans  
Result : negative

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: In vitro mammalian cell gene mutation test

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

Method: OECD Test Guideline 476  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Method: OECD Test Guideline 474  
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Hamster  
Application Route: Ingestion  
Method: OECD Test Guideline 475  
Result: negative

**Ivermectin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: human diploid fibroblasts  
Result: negative

Test Type: Mouse Lymphoma  
Result: negative

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

**Ivermectin / Abamectin Liquid Formulation**

Version 9.1      Revision Date: 30.09.2023      SDS Number: 1210015-00023      Date of last issue: 04.04.2023  
Date of first issue: 10.01.2017

---

**(dl)-a-Tocopheryl acetate:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : inhalation (vapour)  
Exposure time : 2 Years  
Result : negative

**Ivermectin:**

Species : Rat  
Application Route : Oral  
NOAEL : 1.5 mg/kg body weight  
Result : negative  
Remarks : Based on data from similar materials

Species : Mouse  
Application Route : Oral  
NOAEL : 2.0 mg/kg body weight  
Result : negative  
Remarks : Based on data from similar materials

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rat  
Application Route : Oral  
Exposure time : 105 weeks  
Result : negative

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

Species : Mouse  
 Application Route : Oral  
 Exposure time : 93 weeks  
 Result : negative

**(dl)-a-Tocopheryl acetate:**

Species : Rat  
 Application Route : Ingestion  
 Exposure time : 104 weeks  
 Result : negative

**Reproductive toxicity**

May damage the unborn child. Suspected of damaging fertility.

**Components:****N-Methyl-2-pyrrolidone:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 416  
 Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 414  
 Result: positive

Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: inhalation (vapour)  
 Result: positive

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Ingestion  
 Result: positive

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

**Ivermectin:**

Effects on fertility : Test Type: Fertility  
 Species: Rat  
 Application Route: Oral  
 Fertility: NOAEL: 0.6 mg/kg body weight  
 Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Development  
 Species: Mouse

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

Application Route: Oral  
 Developmental Toxicity: NOAEL: 0.2 mg/kg body weight  
 Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 0.4 mg/kg body weight  
 Result: Embryotoxic effects and adverse effects on the offspring were detected.  
 Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development  
 Species: Rabbit  
 Application Route: Oral  
 Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Effects on fertility : Test Type: Fertility  
 Species: Rat, male  
 Application Route: Oral  
 Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Oral  
 Early Embryonic Development: NOAEL: 0.12 mg/kg body weight  
 Result: Fetotoxicity

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Mouse  
 Application Route: Oral  
 General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight  
 Developmental Toxicity: NOAEL: 0.2 mg/kg body weight  
 Result: Cleft palate  
 Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 2 mg/kg body weight  
 Result: Cleft palate, Teratogenic effects, Reduced embryonic survival  
 Remarks: Adverse developmental effects were observed

Test Type: Development

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 1.6 mg/kg body weight  
 Result: Teratogenic effects

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

**(dl)-a-Tocopheryl acetate:**

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Ingestion  
 Result: negative

**STOT - single exposure**

May cause respiratory irritation.  
 May cause damage to organs (Central nervous system) if swallowed.

**Components:****N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

**Ivermectin:**

Target Organs : Central nervous system  
 Assessment : Causes damage to organs.

**STOT - repeated exposure**

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

**Components:****Ivermectin:**

Target Organs : Central nervous system  
 Assessment : Causes damage to organs through prolonged or repeated exposure.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Exposure routes : Ingestion  
 Target Organs : Central nervous system  
 Assessment : Causes damage to organs through prolonged or repeated



## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

exposure.

**Repeated dose toxicity****Components:****N-Methyl-2-pyrrolidone:**

Species	: Rat, male
NOAEL	: 169 mg/kg
LOAEL	: 433 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Method	: OECD Test Guideline 408

Species	: Rat
NOAEL	: 0.5 mg/l
LOAEL	: 1 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 96 Days
Method	: OECD Test Guideline 413

Species	: Rabbit
NOAEL	: 826 mg/kg
LOAEL	: 1,653 mg/kg
Application Route	: Skin contact
Exposure time	: 20 Days

**Ivermectin:**

Species	: Dog
NOAEL	: 0.5 mg/kg
LOAEL	: 1 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Target Organs	: Central nervous system
Symptoms	: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species	: Monkey
NOAEL	: 1.2 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Remarks	: No significant adverse effects were reported

Species	: Rat
NOAEL	: 0.4 mg/kg
LOAEL	: 0.8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: spleen, Bone marrow, Kidney

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species	: Rat
---------	-------

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

NOAEL : 1.5 mg/kg  
 Application Route : Oral  
 Exposure time : 24 Months  
 Target Organs : Central nervous system  
 Symptoms : Tremors, ataxia

Species : Mouse  
 NOAEL : 4.0 mg/kg  
 Application Route : Oral  
 Exposure time : 24 Months  
 Target Organs : Central nervous system  
 Symptoms : Tremors, ataxia

Species : Dog  
 NOAEL : 0.25 mg/kg  
 LOAEL : 0.5 mg/kg  
 Application Route : Oral  
 Exposure time : 53 Weeks  
 Target Organs : Central nervous system  
 Symptoms : Tremors, weight loss  
 Remarks : mortality observed

Species : Monkey  
 NOAEL : 1.0 mg/kg  
 Application Route : Oral  
 Exposure time : 14 Weeks  
 Target Organs : Central nervous system

**(dl)-a-Tocopheryl acetate:**

Species : Rat  
 NOAEL : 500 mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****N-Methyl-2-pyrrolidone:**

Skin contact : Symptoms: Skin irritation

**Ivermectin:**

Skin contact : Remarks: Can be absorbed through skin.  
 Eye contact : Remarks: May irritate eyes.  
 Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Ingestion : Symptoms: May cause, Tremors, Diarrhoea, central nervous

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

system effects, Salivation, tearing

---

**Section 12: Ecological information**
**Ecotoxicity****Components:****N-Methyl-2-pyrrolidone:**

- |  |   |  |
|--|---|--|
| Toxicity to fish   | : | LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l<br>Exposure time: 96 h  |
| Toxicity to daphnia and other aquatic invertebrates                    | : | EC50 (Daphnia magna (Water flea)): > 1,000 mg/l<br>Exposure time: 24 h<br>Method: DIN 38412  |
| Toxicity to algae/aquatic plants                                       | : | ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l<br>Exposure time: 72 h<br><br>EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l<br>Exposure time: 72 h |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC (Daphnia magna (Water flea)): 12.5 mg/l<br>Exposure time: 21 d<br>Method: OECD Test Guideline 211   |
| Toxicity to microorganisms   | : | EC50: > 600 mg/l<br>Exposure time: 30 min<br>Method: ISO 8192  |

**Ivermectin:**

- |   |   |  |
|---|---|--|
| Toxicity to fish                                    | : | LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l<br>Exposure time: 96 h<br><br>LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l<br>Exposure time: 96 h   |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 0.000025 mg/l<br>Exposure time: 48 h  |
| Toxicity to algae/aquatic plants                    | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201<br><br>NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201 |
| M-Factor (Acute aquatic tox-                        | : | 10,000   |

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

icity)

M-Factor (Chronic aquatic toxicity) : 10,000

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l  
Exposure time: 96 hLC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l  
Exposure time: 96 hLC50 (Ictalurus punctatus (channel catfish)): 24 µg/l  
Exposure time: 96 hLC50 (Cyprinus carpio (Carp)): 42 µg/l  
Exposure time: 96 hLC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l  
Exposure time: 96 hToxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 0.022 µg/l  
Exposure time: 96 hEC50 (Daphnia magna (Water flea)): 0.34 µg/l  
Exposure time: 48 hToxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l  
Exposure time: 72 h

M-Factor (Acute aquatic toxicity) : 10,000

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l  
Exposure time: 32 dToxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.03 µg/l  
Exposure time: 21 dNOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l  
Exposure time: 28 d

M-Factor (Chronic aquatic toxicity) : 10,000

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition**(dl)-a-Tocopheryl acetate:**Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

**Ivermectin / Abamectin Liquid Formulation**

Version 9.1      Revision Date: 30.09.2023      SDS Number: 1210015-00023      Date of last issue: 04.04.2023  
Date of first issue: 10.01.2017

---

- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l  
Exposure time: 28 d
- Toxicity to microorganisms : EC50: > 927 mg/l  
Exposure time: 30 min  
Method: ISO 8192

**Persistence and degradability****Components:****N-Methyl-2-pyrrolidone:**

- Biodegradability : Result: Readily biodegradable.  
Biodegradation: 73 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301C

**Ivermectin:**

- Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 240 d

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

- Stability in water : Hydrolysis: 50 %(< 12 h)

**(dl)-a-Tocopheryl acetate:**

- Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 21.7 - 31 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301C

**Bioaccumulative potential****Components:****N-Methyl-2-pyrrolidone:**

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

Partition coefficient: n-octanol/water : log Pow: -0.46  
Method: OECD Test Guideline 107

**Ivermectin:**

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

**Mobility in soil****Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environmental compartments : log Koc: > 3.6

**Other adverse effects**

No data available

---

**Section 13: Disposal considerations****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**Section 14: Transport information****International Regulations****UNRTDG**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3082

---

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 964

Packing instruction (passenger aircraft) : 964

Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9

Packing group : III

Labels : 9

EmS Code : F-A, S-F

Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****NZS 5433**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9

Packing group : III

Labels : 9

Hazchem Code : 3Z

Marine pollutant : no

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**Section 15: Regulatory information****Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

not allocated

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

**The components of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

---

**Section 16: Other information**

Revision Date : 30.09.2023

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH BEI	:	ACGIH - Biological Exposure Indices (BEI)
NZ OEL	:	New Zealand. Workplace Exposure Standards for Atmospheric Contaminants
NZ OEL / WES-TWA	:	Workplace Exposure Standard - Time Weighted average
NZ OEL / WES-STEL	:	Workplace Exposure Standard - Short-Term Exposure Limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation,



**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	1210015-00023	Date of first issue: 10.01.2017

---

tion, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN